Novavax shares surge 21.45% after-hours after securing $530M licensing deal with Pfizer for Matrix-M adjuvant technology.

Novavax (NVAX) surged 21.45% in after-hours trading following the announcement of a $530 million licensing agreement with Pfizer for its Matrix-M adjuvant technology. The non-exclusive deal grants Pfizer access to Novavax’s immune-boosting adjuvant for use in up to two infectious disease areas, with Novavax receiving a $30 million upfront payment, potential $500 million in development and sales milestones, and tiered royalties on future product sales. This partnership, highlighted across multiple reports, underscores Matrix-M’s strategic value in vaccine development and signals strong commercial potential for Novavax. The stock’s significant post-market rally reflects investor optimism over the deal’s immediate financial terms and long-term revenue opportunities, aligning with the company’s growth strategy in the vaccine adjuvant market.